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Do female patients with metabolic syndrome have 
masked left ventricular dysfunction?
Metabolik sendromlu kad›nlarda gizli sol ventrikül disfonksiyonu mu var?
Objective: Metabolic syndrome (MS) is a condition, which is recognized as raising the risk of cardiovascular disease. The aim of our study
is to estimate the left ventricular functions by atrioventricular plane displacement (AVPD), myocardial performance index (MPI) and con-
ventional methods in patients with MS who were diagnosed according to NCEP (ATP III) criteria. 
Methods: Fifty-three female patients with MS (mean age 53.1±6.9 years) and 30 healthy female subjects (mean age 52.8±6.3 years, p>0.05)
underwent complete echocardiographic assessment. All of the subjects had no heart and pulmonary diseases. The systolic mitral AVPD
was recorded at 4 sites (septal, lateral, anterior, and posterior) by M-mode echocardiography and left ventricle ejection fraction (LVEF)
was calculated from the AVPD-mean (EF-AVPD). The LVEF was also established by biplane Simpson’s (EF-2D) and Teichholz’s methods
(EF-T). Left ventricular MPI was calculated as (isovolumic contraction time + isovolumic relaxation time) / aortic ejection time by Dopp-
ler echocardiography.
Results: Patients with MS showed mild left ventricular diastolic dysfunction (DD) in comparison to healthy subjects. The EF-2D and EF-T
in patients with MS and healthy subjects were not different significantly and were within normal limits. Patients with MS showed LV glo-
bal dysfunctions compared to healthy subjects (MPI: 0.56±0.12 and 0.46±0.11 respectively, p<0.01). Both the septal, anterior, lateral and
posterior part of the atrioventricular plane values and also AVPD-mean during systole were statistically lower in patients with MS
(12.85±1.76 mm) as compared with controls (14.65±2.19 mm, p<0.05). EF-AVPD in patients with MS was statistically lower (65.58 ±11.95%)
as compared with healthy subjects (74.45±11.07 %, p<0.01). 
Conclusion: Female patients with MS had both left ventricular DD and a global dysfunction with an increased MPI. The EF-2D and EF-T
were not different significantly between patients and controls, but patients with MS had a relatively reduced EF-AVPD. The AVPD met-
hod may indicate a systolic dysfunction with a relatively lower AVPD-mean and relatively lower EF-AVPD. The presence of global
dysfunction in patients with MS may lead to heart failure. (Anadolu Kardiyol Derg 2005; 5: .283-8)
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Amaç: Metabolik sendrom (MS), kardiyovasküler hastal›k riskini art›rd›¤› kabul edilen bir durumdur. Bu çal›flman›n amac›, NCEP (ATP III)
kriterlerine göre MS tan›s› konmufl hastalarda, sol ventrikül fonksiyonlar›n› atriyoventriküler plan yer de¤iflimi (AVPD), miyokardiyal per-
formans indeksi (MP‹) ve konvansiyonel metodlarla de¤erlendirmektir.
Yöntemler: Metabolik sendromlu 53 kad›n hasta (ortalama yafl 53.5±6.9 y›l) ve 30 sa¤l›kl› kad›n (ortalama yafl 52.7±6.3 y›l, p>0.05) tam eko-
kardiyografik de¤erlendirmeye al›nd›. Olgular›n hiçbirinde kalp ve akci¤er hastal›¤› yoktu. Sistolik mitral AVPD 4 bölgeden (septal, lateral,
anteriyor ve posteriyor) M-mod ekokardiyografi ile ölçüldü ve ortalama AVPD’den sol ventrikül ejeksiyon fraksiyonu (EF) hesapland› 
(EF-AVPD). Sol ventrikül EF, ayr›ca biplan Simpson (EF-2D) ve Teichholz (EF-T) metodlar›yla da de¤erlendirildi. Miyokardiyal performans
indeksi, Doppler ekokardiyografi ile (isovolümik kontraksiyon zaman› + isovolümik relaksasyon zaman›) / aortik ejeksiyon zaman›) formü-
lünden hesapland›.
Bulgular: Metabolik sendromlu kad›nlar, sa¤l›kl› kiflilerle k›yasland›¤›nda hafif sol ventrikül diyastolik disfonksiyonu (DD) gösterdiler. Has-
ta ve kontrol gruplar›nda EF-2D ve EF-T anlaml› fark oluflturmad› ve normal s›n›rlardayd›. Metabolik sendromlu hastalar sa¤l›kl› kiflilere gö-
re sol ventrikül global disfonksiyonu gösterdiler (MP‹ s›ras›yla 0.56±0.12 ve 0.46±0.11, p<0.01). Hem septal, anteriyor, lateral ve posteriyor
atriyoventriküler plan ve hem de ortalama sistolik AVPD, MS’lu hastalarda, sa¤l›kl› kiflilere göre anlaml› olarak daha düflüktü (s›ras›yla
12.85±1.76 mm ve 14.65±2.19 mm, p<0.05). Yine MS’lu hastalarda EF-AVPD, kontrol grubuna göre, istatistiksel olarak daha düflüktü (s›ra-
s›yla %65.58 ±11.95 ve %74.45±11.07, p<0.01). 
Sonuç: Metabolik sendromlu kad›n hastalar hem sol ventrikül DD’na ve hem de artm›fl MP‹ de¤erleriyle global disfonksiyona sahiptiler.
Hasta ve kontrol gruplar›nda EF-2D ve EF-T anlaml› fark oluflturmad›; ancak MS’lu hastalar, göreceli olarak azalm›fl EF-AVPD de¤erlerine
sahiplerdi; AVPD metodu, göreceli olarak düflük ortalama AVPD ve EF-AVPD de¤erleri ile sistolik disfonksiyona iflaret edebilir. Metabolik
sendromlu hastalarda ayn› zamanda global disfonksiyonun varl›¤›, kalp yetersizli¤ine yol açabilir. (Anadolu Kardiyol Derg 2005; 5: 283-8)
Anahtar kelimeler: Metabolik sendrom, atriyoventriküler plan yer de¤iflimi, miyokardiyal performans indeksi
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Introduction
Metabolic syndrome (MS) (1), dysmetabolic syndrome or in-
sulin-resistance syndrome (2) or syndrome X as it was initially
designated (3), which is closely linked to insulin resistance, is a
condition which is recognized as raising the risk of cardiovascu-
lar disease. It was originally described by Reaven (3) as a quar-
tet of hypertension, glucose intolerance and dyslipidemia (high
triglyceride, low high-density lipoprotein-cholesterol (HDL-C)),
with insulin resistance or hyperinsulinemia. Central obesity is
often associated (4). The new National Cholesterol Education
Program (NCEP) guidelines (Adult Treatment Panel (ATP) III) (5)
recognized MS as a secondary target of risk-reduction therapy
and selected to define MS when three or more of certain five
risk determinants are present.
The left ventricular (LV) systolic and diastolic functions are
closely related to mortality and morbidity. Arterial hypertension
(HT), evidence of left ventricular hypertrophy (LVH), and coro-
nary artery disease (CAD) are independent predictors of diasto-
lic dysfunction (DD). In addition to these factors, DD is related to
high body mass index (BMI), high body fat mass, and diabetes
mellitus (DM) (1-5). In a previous study, we suggested that insu-
lin resistance might be an important factor causing LV dysfunc-
tion and wall thickness in non-diabetic patients with HT(6,7). Di-
astolic dysfunction precedes LV systolic impairment and acco-
unts alone for about 30–40% of patients with LV failure (8). Early
recognition and appropriate therapy of DD is advisable to pre-
vent further progression to heart failure (HF) and death (9,10). 
Several echocardiographic methods provide quantitative
analysis of LV volumes and ejection fraction (EF) based on the
precise tracing of endocardial borders (11-14). In M-mode echo-
cardiography Teichholz’s formula is the most commonly used
equation for calculation of EF, based on short axis diameter re-
duction. Simpson’s rule is the most commonly used two-dimen-
sional (2D) echocardiographic method for estimation of EF. The
short-axis systolic diameter reduction, the long-axis shortening,
and a combination of these have been used for calculation of
left ventricular EF. Doppler tissue imaging of the mitral annulus
may be used to determine LV systolic and diastolic functions.
However, technically limited studies prohibit such direct analy-
sis, and alternative techniques must be applied. 
The mitral atrioventricular plane displacement (AVPD) met-
hod has been shown to be a reliable and simple technique to
study left ventricular systolic function in patients, because the
mitral annulus can be visualized in almost all patients even if the
endocardial borders are difficult to trace (15-24). The contracti-
on of LV involves both a reduction in diameter of the cylindrical
portion and a shortening alone the longitudinal axis of the cham-
ber. During ventricular systole the AV plane moves towards the
apex of the heart, while during diastole the AV plane rapidly as-
cends towards the left atrium (17,18). The mitral AVPD also may
reflect the left ventricular diastolic function (23). However, myo-
cardial performance index (MPI, Tei index) reflects LV global
(systolic and diastolic) functions (25). A relationship between
MPI and left ventricular geometry was established in hyperten-
sive patients, and the left ventricular global dysfunction was
more advanced in patients with concentric hypertrophy than the
other LV geometric patterns (26).
In order to show if the patients with MS have masked systo-
lic dysfunction or not, we aimed to assess the left ventricular
functions by AVPD, MPI and conventional methods in these pati-
ents who were diagnosed according to NCEP (ATP III) criteria (5). 
Methods
Study population
Fifty-three female patients with MS (mean age 53.5±6.9 ye-
ars) and 30 healthy female subjects (mean age 52.7±6.3 years,
p>0.05) underwent complete echocardiographic assessment.
All of the subjects in both groups had no heart and pulmonary
diseases based on physical examination, and also their electro-
cardiograms were normal, and in sinus rhythm. All of them un-
derwent treadmill exercise test and the test was normal. Systo-
lic (SBP) and diastolic (DBP) blood pressures were measured in
the sitting position on the right arm using an aneroid sphygmo-
manometer (Erka, Germany), after at least 5 min of rest. First ap-
pearance and disappearance (phase V) of Korotkoff's sounds
were used to define the pressures. Readings were recorded to
the nearest even number, and the mean of two recordings 3 min
apart was computed. Heart rate per minute (HR) was measured
in the sitting position. Waist circumference (WC) was measu-
red with the subject standing and wearing only underwear, at
the level midway between the lower rib margin and the iliac
crest, while that of the hip was measured at the level of the gre-
ater trochanters. Body mass index (BMI) was calculated by a
computer as weight divided by height squared (kg/m2). After an
overnight fasting (at least 12 hours) blood glucose (FBG), trigly-
cerides (TG), high-density lipoprotein cholesterol (HDL-C) were
analysed with commercial kits (Abbott, USA) by an autoanaly-
ser (Aeroset, USA). On the other hand, in non-diabetic subjects
75 g oral glucose tolerance test was performed. 
Identification of MS conformed to the definition used by the
NCEP (ATP III)(5), namely when three or more of the following fi-
ve risk determinants were present: WC (in men >102 cm, in wo-
men >88 cm), TG ≥150 mg/dl, HDL-C (in men <40, in women <50
mg/dl), blood pressure (≥130 / ≥85 mmHg), and FBG ≥110 mg/dl. 
Echocardiographic measurements
All measurements were performed with the subjects in the
left lateral decubitus position by M-mode, two-dimensional (2D),
and Doppler ultrasound echocardiography according to the re-
commendations of the American Society of Echocardiography
(27-29). The ultrasound equipment used was Contron Sigma Iris
with a 2.5–MHz probe. Basic measurements of LV dimensions in
diastole and systole, thickness of interventricular septum (IVS)
and posterior wall (LVPW), and also LV mass (LVM) using Deve-
reux formula were measured by the M-mode technique (30).
LVM was divided with body surface area to obtain left ventricu-
lar mass index (LVMI). Left ventricular EF by Simpson’s biplane
method (EF-2D) was calculated as (diastolic volume-systolic vo-
lume)/(diastolic volume). Also, left ventricular EF was calculated
as Teichholz’s short axis method (EF-T). Early (E) and atrial (A)
transmitral maximal flow velocities, the ratio (E/A) and decelera-
tion time of E was registered. Isovolumic relaxation time was
measured by the continuous wave Doppler technique. The velo-
city of mitral flow propagation (VPR) was estimated using color
Doppler M-mode (31). The left ventricular MPI was calculated
as (isovolumic contraction time + isovolumic relaxation time) /
aortic ejection time) (25).
From apical 4- and 2-chamber views the displacement of the
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the left ventricle using M-mode, according to the methods of
Willenheimer and colleagues (21). The regional displacement
(mm) was the distance covered by the AV plane between the
position most remote from the apex (corresponding to the onset
of contraction) and the location closest to the apex (correspon-
ding to the end of contraction, including any post-ejection shor-
tening), that is, the full extent of the displacement. The septal
and lateral AVPD were measured in the four-chamber view and
anterior and posterior AVPD-in the two-chamber view. The me-
an value of the AVPD from the above 4 sites (AVPD-mean) exp-
ressed in mm was calculated from the above four sites. All me-
asurements were performed on three consecutive beats and
the mean values were given. No measurements were made wit-
hin five cycles of an ectopic beat. 
Left ventricular EF was calculated using the regression equ-
ation by Alam et al, (22) describing the relation between the left
ventricular EF, determined by radionuclide ventriculography,
and echocardiographically assessed AVPD:
EFAVPD = (5.5 X mean AVPD) - 5
Statistical analysis
Statistical analyses were performed using Statistical Package
for Social Sciences version 10.0 (SPSS-10.0) for Windows packet
program. Results were given as mean±standard deviation, diffe-
rences between measurements were assessed using indepen-
dent t- test. Correlations between variables were tested assuming
a linear relationship. A P-value<0.05 was considered significant. 
Results
Basic characteristics of patients and healthy subjects
Characteristics of patients with MS and healthy subjects
are shown in Table 1. Patients with MS had significantly higher
WC (p<0.001), higher BMI (p<0.01), higher SBP (p<0.01) and DBP
(p<0.01), higher FBG (p<0.01) and TG (p<0.001) but, had lower
HDL-C (p<0.001) than healthy female subjects. However, waist-
to-hip ratio (WHR) and HR were not different statistically betwe-
en patients and controls (p>0.05). 
Basic echocardiographic parameters
Assessment of left ventricular diameters and functions in pa-
tients with MS and healthy subjects was shown in Table 2 and 3
respectively. Thickness of IVS, LVPW and LVM in patients were
higher than in controls (p<0.05 for all). However, LVMI did not dif-
fer significantly between patients and controls (p>0.05). Although
parameters of diastolic function were in normal limits in healthy
subjects, patients with MS had mild DD. Systolic functions by
conventional method (EF-2D and EF-T) were not different signifi-
cantly between patients (69.2±4.7% and 68.3±3.5%) and controls
(70.6±4.5%, p>0.05 and 70.1±4.0%, p>0.05) and were in normal li-
mits in both groups. On the other hand, patients with MS showed
LV global dysfunctions compared to healthy subjects (MPI:
0.56±0.12 and 0.46±0.11 respectively, p<0.01).
AVPD
The displacements at four sites (septal, anterior, lateral and
posterior part of the atrioventricular plane) in both groups were
Patients with MS Healthy subjects p 
(n=53) (n=30)
Mean age 53.5±6.9 52.7±6.3 NS
WC (cm) 101.3±10.7 90.4±11.7 0.001
WHR 0.88±0.5 0.86±0.4 NS
BMI (kg/m2) 31.5±4.7 27.9±4.7 0.01
HR (pulse/min) 76.0±10.2 78.4±7.4 NS
SBP (mmHg) 132.1±22.9 118.8±10.9 0.01
DBP (mmHg)             83.5±10.2          76.6±6.8 0.01  
FBG (mg/dl) 112.2 ± 33.4 90.0 ± 10.2          0.01
Insulin    (UIU/ml) 10.3±4.8 8.6±2.9 NS
TG (mg/dl) 146.9±60.7 93.2±41.1 0.001
HDL-C (mg/dl) 41.3±6.9 53.8±13.1 0.001
TC (mg/dl) 205.0±42.8 198.2±39.3 NS
BMI: Body, mass index, DBP: Diastolic blood pressure, FBG: Fasting blood glucose, 
HDL-C: High-density lipoprotein cholesterol, HR: Heart  rate per minute,  
NS: Not significant, SBP: Systolic blood pressure, TG: Triglyceride,
TC: Total cholesterol,  WC: Waist circumference, WHR: Waist-to-hip ratio
Table 1. Basic characteristics of patients with metabolic syndrome
(MS)  and healthy subjects
Patients with Healthy subjects p 
MS (n=53) (n=30)
Systolic functions
EF-2D (%) 69.2±4.7 70.6±4.5 NS
EF-T (%)                   68.3±3.5 70.1±4.0 NS
EF-AVPD (%) 65.6±12.0  74.5±11.1 0.01
FS (%) 39.1±4.1 39.9±4.0 NS
Diastolic functions
E-vel.  (m/s) 0.8±0.2 0.8±0.2 NS
A-vel.  (m/s) 1.1±1.4 0.7±0.2 NS
E/A ratio 0.9±0.3 1.2±0.4 0.001
DT (ms) 237.2±36.0 208.5±50.1 0.01
IVRT (ms) 108.2±23.0 79.8±16.7 0.001
VPR (cm/s) 45.0±23.2 92.3±50.6 0.001
Global function
MPI 0.56±0.12 0.46±0.10 0.01
A- vel.: late mitral flow velocity, DT:deceleration time, E- vel.: early mitral flow velocity,
E/A ratio: ratio of early and late mitral flow velocities, EF-AVPD: left ventricular ejection
fraction by atrioventricular plane displacement method, EF-2D: left ventricular ejection
fraction in 2 dimensional echocardiography, EF-T: ejection fraction by Teicholz, FS: frac-
tion shortening, IVRT: isovolumic relaxation time, MPI: myocardial performance index,
VPR: mitral flow propagation, NS: nonsignificant
Table 3. Assessment of left ventricular functions by echocardiography
in patients with metabolic syndrome (MS)  and healthy subjects
Patients with Healthy subjects p 
MS (n=53) (n=30)
Left atrium (mm) 37.7±3.6 35.1±4.6 0.01
IVS Thickness (mm) 10.8±1.4 10.0±1.4 0.05
LVPW Thickness (mm) 10.5±1.1 9.8±1.2 0.05
LVM (g)                             210.4±48.7 182.3±45.3 0.05
LVMI (g/m2)                       114.8±23.4       105.9±22.7 NS
LVED Diameter (mm) 47.3±4.7 45.7±3.7 NS
LVES Diameter (mm) 29.2±3.8 27.6±2.9 NS
LVED Volume (ml) 104.3±23.5 98.3±20.3 NS
LVES Volume (ml) 32.3±9.8 28.5±8.7 NS
IVS: Interventricular septum, LVED: Left ventricular end diastolic, 
LVES: Left ventricular end systolic, LVM: Left ventricular  mass, 
LVMI: Left ventricular mass index, LVPW: Posterior left ventricular wall, NS: Not significant
Table 2. Assessment of left ventricular mass and diameters by echocardi-
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shown in Table 4. Both the septal, anterior, lateral and posterior
part of the atrioventricular plane values and also AVPD-mean
during systole were statistically lower in patients with MS
(12.8±2.2 mm) as compared with healthy subjects (14.5±2.0 mm,
p<0.01). The EF-AVPD was statistically lower in patients
(65.6±12.0 %) as compared with healthy subjects (74.5±11.1 %,
p<0.01). 
Correlations
Significantly positive correlations were shown between EF-
AVPD and EF-2D (r =0.707, p<0.01) and EF-T (r =0.818, p<0.01)
(Fig.1). Also, a significantly positive correlation was shown bet-
ween EF-2D and EF-T (r =0.645, p<0.01). However, EF-AVPD was
negatively correlated with MPI (r = -0.500, p<0.01) (Fig.2).
Discussion
It is well known that important cardiovascular risk factors,
such as hypertension, glucose intolerance, hyperinsulinemia,
dyslipidemia, and obesity, often cluster in the same individuals.
Therefore, the existence of a syndrome involving these disor-
ders has been proposed in which insulin resistance has been
suggested to be of particular importance (3,32,33). An associati-
on between this insulin resistance syndrome and left ventricular
hypertrophy (LVH) has recently been found (32,33). Characteris-
tically, cardiac hypertrophy is secondary to hypertension, but
some degree of cardiac hypertrophy can also be found in nor-
motensive obese subjects (24), in patients with ischemic heart
disease (35), and in diabetic patients (36). Insulin resistance co-
uld influence myocardial morphology and function in several
ways, because insulin resistance is associated with hyperinsu-
linemia, which is known to induce growth of myocardial tissue
in vitro (34).
In our study, in patients with MS, IVS and LVPW thick-
nesses, left atrial diameter and LVM were found to be incre-
ased, but not LVMI in comparison to healthy subjects. Mild left
ventricular DD was shown in patients with MS compared with
healthy subjects. Although the EF-2D and EF-T between patients
with MS and healthy subjects were not different significantly,
and were in normal limits; AVPD-mean during systole and EF-
AVPD were statistically lower in patients with MS compared
with healthy subjects. Also, patients with MS had statistically
higher MPI than healthy subjects reflecting left ventricular glo-
bal dysfunction. These results show that the patients with MS
and apparently preserved systolic function, as assessed by con-
ventional methods, may have an unrecognized reduction in left
ventricular contractility, and suggest left ventricular global
dysfunction in addition to presence of mild DD. 
In our study patients DD might be dependent on risk deter-
minants (especially blood pressure, FBG and abdominal obesity)
of metabolic syndrome. However, none of the patients with MS
had clinically overt CAD, and all of them had electrocardiograp-
hically normal treadmill exercise tests. A strong correlation bet-
ween BMI and, in particular, an elevated body fat mass with HT
and LVH was demonstrated (34). The correlation between an
elevated fat mass and diastolic dysfunction may result from
pressure overload and a disproportional increase of IVS and
LVPW thickness in obese individuals. This is also in agreement
with our findings. 
Most traditional echocardiographic methods for determi-
ning left ventricular EF have some disadvantages, limiting their
use (17,18). Long axis fibres are mainly subendocardial and mo-
re prone to ischaemia, implying that abnormalities of AVPD may
occur earlier in the disease process and represent more subtle
alterations in ventricular function. The systolic mitral AVPD is
quite different from left ventricular EF and other conventional
measurements of left ventricular systolic function. The contrac-
Patients with Healthy subjects p 
MS (n=53) (n=30)
AVPD-septal (mm) 12.5±1.9 14.0±2.2             0.01
AVPD-lateral (mm) 13.1±2.7 15.1±2.2 0.01
AVPD-anterior (mm) 12.8±2.5 14.3±2.1               0.01
AVPD-posterior (mm) 12.9±2.5 14.4±2.1               0.01
AVPD-mean (mm) 12.8±2.2 14.5±2.0               0.01
EF-AVPD (%) 65.6±12.0  74.5±11.1             0.01
AVPD: Atrioventricular plane displacement, EF-AVPD: Left ventricular ejection fraction
from atrioventricular plane displacement method. 
Table 4. Assessment of left ventricular systolic function by AVPD met-
hod in patients with metabolic syndrome (MS)  and healthy subjects
Figure 1. Correlations between EF-AVPD and EF-2D
EFAVPD: Left ventricular ejection fraction by atrioventricular plane displacement method,
EF-2D: Left ventricular ejection fraction in 2 dimensional echocardiography, EF-T: Left ven-
tricular ejection fraction by Teichholz’s method
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Figure 2. Correlations between EF-AVPD and myocardial perfor-
mance index
EFAVPD: Left ventricular ejection fraction by atrioventricular plane displacement method,
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tion of left ventricle involves both a reduction in diameter of the
cylindrical portion and a shortening alone the longitudinal axis
of the chamber. The left ventricular pump function has traditi-
onally been attributed mainly to the circumferentially orientated
myocardial fibres (17-20). The mitral AVPD may better reflect left
ventricular systolic function and may ultimately prove to be a
more accurate prognostic indicator than EF despite left ventri-
cular asymmetry, since it is determined in four different regions
(the septal, lateral, posterior and anterior regions) of the left
ventricle, and since it may evaluate the total shortening along
the left ventricular long axis in the respective regions. However,
the correlation between AVPD and reliable indices of left vent-
ricular systolic function is very strong (r values> 0.8) (21,22). The
correlations between AVPD and EF-2D and EF-T were signifi-
cantly strong in our study patients (r = 0.707, p<0.01 and r = 0.818,
p<0.01, respectively). More important, reduced systolic mitral
AVPD is a powerful predictor of poor prognosis (20,21). Morta-
lity is significantly higher when the AVPD is less than 10 mm with
a substantial mortality increase when AVPD is less than 7 mm
(21). However, in our study population there was no subject who
had an AVPD< 10 mm.
The predominant role of HT for the development of diastolic
heart failure was initially established by the Framingham Heart
Study (37). Diastolic dysfunction in hypertensive patients can
occur even in the absence of structural myocardial abnormaliti-
es and represents usually myocyte dysfunction with impaired
isovolumic relaxation. Left ventricular diastolic filling is a comp-
lex event that is influenced by several factors, such as preload,
heart rate, left ventricular relaxation, left ventricular complian-
ce, left atrium contraction force and afterload (32). Thus, left
ventricular DD might be the result of a variety of impairments.
Hypertension commonly occurs in type 2 DM, and contribu-
tes importantly to the heightened risk of cardiovascular, renal,
and retinal disease (36). Diabetes mellitus might predispose to
left ventricular systolic and diastolic dysfunctions indepen-
dently of concurrent coronary or rheumatic heart disease (38).
Histology in diabetics is largely indistinguishable from changes
found in hypertensive left ventricular disease. Specific myocar-
dial disease in DM commonly is called “diabetic cardiomyo-
pathy”. The pathogenesis is unclear, although possible mecha-
nisms include the synergistic impact of hypertension plus chro-
nic derangement of myocardial metabolism, with increased free
fatty acid oxidation and decreased glucose utilisation (39). 
Left ventricular systolic and/or diastolic functions provide
prognostic information in patients. So, the AVPD method may in-
dicate a systolic dysfunction with a relatively lower AVPD-mean
and relatively lower EF-AVPD in patients with MS compared
with healthy subjects. This indicated the presence of normal,
but statistically significant decrease of left ventricular systolic
function by AVPD method in patients with MS. Diastolic abnor-
malities may represent an early cardiac abnormality in subjects
with such risk factors who may develop, as a consequence,
functional abnormalities of the heart including DD. Also signifi-
cantly higher MPI in patients with MS may reflect left ventricu-
lar global dysfunction. It might be suggested that DD might be
combined with systolic dysfunction rather than presence of iso-
lated diastolic dysfunction in patients with MS. 
As a result, our findings may suggest that female patients
with MS who have DD may prone to develop systolic dysfuncti-
on also. So, the presence of global dysfunction in patients with
MS may lead to heart failure. The mitral AVPD and MPI may be
useful and simple non-invasive methods for the estimation of left
ventricular systolic and global functions in patients with MS. 
Study limitations
One of the our study limitations is that there are no other
more sophisticated markers of diastolic function available such
as Doppler tissue imaging of mitral annular motion or pulmonary
venous flow signals. Since the ventricular systolic and/or dias-
tolic functions provide prognostic information in the patients
with MS, our results should be further confirmed with larger
prospective studies.
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